Yu-Li Chen1, Wen-Fang Cheng, Ming-Cheng Chang, Han-Wei Lin, Ching-Ting Huang, Chung-Liang Chien, Chi-An Chen. 1. Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan; Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract
OBJECTIVE: The ovarian cancer-associated ascites is an ideal material for evaluating the interaction between the host immune system and cancer cells in the tumor micro-environment. The aim of this study was to investigate whether the selected target cytokine expression levels in ascites could serve as an immune biomarker for predicting outcomes in ovarian cancer. METHODS: Eighty-eight specimens of ovarian cancer-associated ascites were evaluated to select the target cytokine by a cytokine profiling kit. The 144 total samples were subsequently analyzed for this target cytokine. The correlation between the target cytokine and clinical characteristics was analyzed. RESULTS: Interferon-gamma (IFN-γ) was identified as the target cytokine. Higher levels of IFN-γ in the ascites of the tumor micro-environment were associated with advanced disease (p=0.012), higher tumor histological grading (p=0.004), and sub-optimal surgical status (p=0.040). By multivariate analysis, the adjusted hazard ratios (HRs) were 2.74 (95% confidence interval (CI) 1.85-4.05, p<0.001) for disease-free survival (DFS) and 1.72 (95% CI 1.01-2.93, p=0.048) for overall survival (OS) for a 10-fold increase in IFN-γ concentration in the ascites. An inverse dose-response relationship between IFN-γ level and survival was also noted (Ptrend<0.001 for DFS and Ptrend<0.042 for OS). CONCLUSIONS: Patients with ovarian cancer and higher IFN-γ expression levels in cancer-associated ascites will have shorter DFS and OS. IFN-γ levels in the ascites may be a prognostic marker and a potential reference for immunotherapy targeting IFN-γ.
OBJECTIVE: The ovarian cancer-associated ascites is an ideal material for evaluating the interaction between the host immune system and cancer cells in the tumor micro-environment. The aim of this study was to investigate whether the selected target cytokine expression levels in ascites could serve as an immune biomarker for predicting outcomes in ovarian cancer. METHODS: Eighty-eight specimens of ovarian cancer-associated ascites were evaluated to select the target cytokine by a cytokine profiling kit. The 144 total samples were subsequently analyzed for this target cytokine. The correlation between the target cytokine and clinical characteristics was analyzed. RESULTS:Interferon-gamma (IFN-γ) was identified as the target cytokine. Higher levels of IFN-γ in the ascites of the tumor micro-environment were associated with advanced disease (p=0.012), higher tumor histological grading (p=0.004), and sub-optimal surgical status (p=0.040). By multivariate analysis, the adjusted hazard ratios (HRs) were 2.74 (95% confidence interval (CI) 1.85-4.05, p<0.001) for disease-free survival (DFS) and 1.72 (95% CI 1.01-2.93, p=0.048) for overall survival (OS) for a 10-fold increase in IFN-γ concentration in the ascites. An inverse dose-response relationship between IFN-γ level and survival was also noted (Ptrend<0.001 for DFS and Ptrend<0.042 for OS). CONCLUSIONS:Patients with ovarian cancer and higher IFN-γ expression levels in cancer-associated ascites will have shorter DFS and OS. IFN-γ levels in the ascites may be a prognostic marker and a potential reference for immunotherapy targeting IFN-γ.
Authors: Nonna Kolomeyevskaya; Kevin H Eng; Anm Nazmul H Khan; Kassondra S Grzankowski; Kelly L Singel; Kirsten Moysich; Brahm H Segal Journal: Gynecol Oncol Date: 2015-05-20 Impact factor: 5.482
Authors: Stephen F Madden; Colin Clarke; Britta Stordal; Mark S Carey; Russell Broaddus; William M Gallagher; John Crown; Gordon B Mills; Bryan T Hennessy Journal: Mol Cancer Date: 2014-10-24 Impact factor: 27.401
Authors: Dagmar Quandt; Hans Dieter Zucht; Arno Amann; Anne Wulf-Goldenberg; Carl Borrebaeck; Michael Cannarile; Diether Lambrechts; Herbert Oberacher; James Garrett; Tapan Nayak; Michael Kazinski; Charles Massie; Heidi Schwarzenbach; Michele Maio; Robert Prins; Björn Wendik; Richard Hockett; Daniel Enderle; Mikkel Noerholm; Hans Hendriks; Heinz Zwierzina; Barbara Seliger Journal: Oncotarget Date: 2017-07-18
Authors: Judith E den Ouden; Guido J R Zaman; Jelle Dylus; Antoon M van Doornmalen; Winfried R Mulder; Yvonne Grobben; Wilhelmina E van Riel; Joanne A de Hullu; Rogier C Buijsman; Anne M van Altena Journal: Oncotarget Date: 2020-12-08